Portola Pharmaceuticals to Host Webcast Event and Conference Call at ACC.18 to Discuss Late-Breaking Oral Presentation Highli...
05 Mars 2018 - 10:10PM
Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that
it will host a live audio webcast and conference call on Monday,
March 12, 2018 at the American College of Cardiology’s 67th Annual
Scientific Session & Expo (ACC.18), following the presentation
of new interim data from the ongoing ANNEXA-4 Phase 3b/4 trial of
the Company’s investigational Factor Xa reversal agent andexanet
alfa, during the Late-Breaking Clinical Trials Session.
The conference call and live audio webcast will
be hosted by Dr. C. Michael Gibson, ANNEXA-4 Executive Committee
member, Harvard Medical School professor and chairman of the
PERFUSE Study Group, who will provide an overview of the interim
results presented during the Late-Breaking Clinical Trials Session.
Dr. Gibson will be joined by Portola management for the Q&A
portion of the call.
ANNEXA-4 Late-Breaking Oral Presentation
Details |
Session: |
(409) Late-Breaking
Clinical Trials Session: Interventional Cardiology |
Title: |
ANNEXA-4: Interim
Report on the ANNEXA-4 Study: Andexanet for Reversal of |
|
Anticoagulation in
Factor Xa-Associated Acute Major Bleeding |
Presenter: |
Stuart J. Connolly,
M.D., Professor Emeritus of Medicine, McMaster University,
Hamilton |
|
Health
Sciences |
Date: |
Monday, March 12, 10:45
a.m. – 11:45 a.m. ET |
Room: |
ACC.18 Main Tent, Hall
C |
Webcast and Conference Call
DetailsTo access the investor webcast and presentation
slides on Monday, March 12 at 12:30 p.m. ET (9:30 a.m. PT), go
to the Investor Relations section of the company’s website at
http://investors.portola.com. The live call can be accessed by
phone by dialing (844) 452-6828 The webcast can be accessed live on
the Investor Relations section of the Company's website
at http://investors.portola.com. It will be archived for 30
days following the call. from the United States and Canada or
1 (765) 507-2588 internationally and using the passcode 8493604.
Analysts and investors interested in attending the in-peron event
in Orlando should RSVP to Cara
Miller at cmiller@portola.com for additional
details.
About Portola Pharmaceuticals,
Inc.Portola Pharmaceuticals is a biopharmaceutical
company developing product candidates that could significantly
advance the fields of thrombosis and other hematologic diseases.
The Company’s first medicine Bevyxxa® (betrixaban), an oral,
once-daily Factor Xa inhibitor, was approved by the U.S. Food
and Drug Administration in June 2017. The company is also
working to advance two clinical programs for andexanet alfa, a
recombinant protein designed to reverse the anticoagulant effect in
patients treated with an oral or injectable Factor Xa inhibitor;
and cerdulatinib, a SYK/JAK inhibitor in development to treat
hematologic cancers. Portola's partnered program is focused on
developing selective SYK inhibitors for inflammatory conditions.
For more information, visit http://www.portola.com and
follow the Company on Twitter @Portola_Pharma.
Investor Contact: Cara MillerPortola
Pharmaceuticalsir@portola.com
Media Contact:Laurie MasonsonW2O
Grouplmasonson@w2ogroup.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur